Centre for Child Health Research, University of Western Australia, Subiaco, W.A., Australia.
Int Arch Allergy Immunol. 2012;158(4):347-58. doi: 10.1159/000334280. Epub 2012 Apr 3.
Innate properties that enhance immune responses might increase the propensity of certain allergens to induce allergic sensitization. Either a direct adjuvant effect or the increased immune response to the allergen could then increase allergic responses to bystander antigens. Here, we report on a model that does not use Th2-skewing adjuvants and yet achieves sensitization solely via the nasal mucosa.
Animals were sensitized with either enzymatically active, inactive or non-activated cysteine proteases via the nasal mucosa. Following two sensitization phases, mice were challenged with a higher dose of allergen. For bystander sensitization, mice received recombinant Der p 2 at sensitization in conjunction with the cysteine protease and were challenged with rDer p 2 alone. Sensitization was determined by measuring allergen-specific antibody responses and cytokine and cellular infiltrates into the lungs following challenge.
Sensitization for Th2-type lung hypersensitivity for both the cysteine protease and bystander antigens was readily achieved and both were dependent on the proteolytic activity of the allergen. Bystander adjuvant activity was demonstrated for mice that were low IgE responders to the cysteine protease, showing a response independent from the immune response to the enhancing cysteine protease. Airway hyperreactivity was induced in the susceptible NOD strain of mouse, and mice subjected to prolonged administration of papain maintained the ability to produce lung hypersensitivity and Th2-type responses.
These experiments demonstrate that cysteine protease activity at low doses can be an adjuvant for respiratory Th2 responses for themselves and bystander antigens in the absence of another adjuvant.
增强免疫反应的先天特性可能会增加某些过敏原诱导过敏致敏的倾向。过敏原的直接佐剂作用或免疫反应增强,都可能增加对旁观者抗原的过敏反应。在这里,我们报告了一种模型,该模型不使用 Th2 偏向佐剂,但仅通过鼻黏膜就能实现致敏。
动物通过鼻黏膜用酶活性、非活性或非激活半胱氨酸蛋白酶进行敏化。在两个敏化阶段后,用更高剂量的过敏原对动物进行挑战。对于旁观者致敏,在敏化时用重组 Der p 2 与半胱氨酸蛋白酶一起给予动物,并单独用 rDer p 2 进行挑战。通过测量挑战后过敏原特异性抗体反应以及细胞因子和细胞浸润到肺部来确定致敏情况。
半胱氨酸蛋白酶和旁观者抗原的 Th2 型肺过敏敏化很容易实现,并且都依赖于过敏原的蛋白水解活性。对于对半胱氨酸蛋白酶低 IgE 反应的小鼠,旁观者佐剂活性得到了证明,表明该反应独立于增强半胱氨酸蛋白酶的免疫反应。在易感 NOD 小鼠中诱导了气道高反应性,并且接受木瓜蛋白酶长期给药的小鼠能够维持产生肺过敏和 Th2 型反应的能力。
这些实验表明,低剂量的半胱氨酸蛋白酶活性本身可以作为呼吸性 Th2 反应的佐剂,并且在没有其他佐剂的情况下,也可以作为旁观者抗原的佐剂。